A new experimental vaccine for acne is set to enter clinical trials, offering hope for patients with the common skin condition. Developed by Sanofi, the vaccine aims to boost the immune system’s response against specific strains of bacteria thought to contribute to acne development.
Acne affects approximately 95% of people between the ages of 11 and 30, causing inflammation in hair follicles and pores, leading to pimple formation on the face, upper arms, trunk, and back. The condition can be triggered by various factors, including hormonal sensitivity, certain medications, genetic factors, and bacteria like Cutibacterium acnes.
Sanofi is conducting a Phase I/II trial, which began in April 2024 and will run until 2027. The trial involves recruiting 400 adults with moderate to severe facial acne, who will receive one of three doses of the vaccine or a “dummy” vaccine. This trial aims to assess the safety and efficacy of the vaccine.
The vaccine works by using mRNA technology, which prompts the immune system to attack specific proteins. In this case, the target proteins are likely related to Cutibacterium acnes bacteria. If successful, the vaccine could provide a new treatment option for acne patients, who often face unwanted side effects from traditional medications, such as skin dryness and depression.
While Sanofi’s vaccine is promising, it’s essential to note that much more testing will be required before it can be licensed and approved for widespread use. The initial trial results are expected sometime after 2027, with a separate Phase I clinical trial planned for patients with milder forms of acne in 2027.
Other researchers have also developed an acne vaccine targeting a specific enzyme variant in Cutibacterium acnes bacteria. This vaccine has shown promising results in mice, reducing the severity of acne by 50%. However, it’s unclear when this vaccine will enter clinical trials.
The development of an acne vaccine offers hope for patients who have suffered from acne, and researchers are eager to contribute to improving treatment options.
Source: https://www.livescience.com/health/medicine-drugs/acne-vaccine-experimental-shot-for-common-skin-condition-reaches-clinical-trials-heres-what-you-need-to-know